The move brings Xeomin and Radiesse to China as part of the company’s broader international expansion.
Merz Aesthetics has launched flagship products Xeomin and Radiesse in China, expanding access to its neuromodulator and dermal filler offerings in the region.
“China is a key strategic market for our global business, and this milestone reflects our incredible momentum as a category leader,” says Bob Rhatigan, CEO of, Merz Aesthetics, in a release “Since becoming a standalone business in 2020, we have consistently outpaced the growth in our industry, and we remain committed to increasing access to our premium products across the world.”
Findings from Merz Aesthetics’ recent Pillars of Confidence Global Study reinforce the cultural embrace of aesthetics in China, with 68% of study respondents saying they have had an aesthetic treatment, versus 35% of U.S. respondents.
“China’s medical aesthetics community is rapidly evolving, and we are honored to support customers and their patients with advanced, clinically proven solutions for their dynamic needs,” said Lawrence Siow, president of Merz Aesthetics Asia Pacific, in a release. “Our commitment in China goes beyond products. We invest in education, training, and true partnerships to help practitioners deliver customized results and empower patients to feel confident.”
In the United States, Radiesse was first approved by the US Food and Drug Administration in 2006, with Xeomin receiving its first FDA approval in 2010.
Photo caption: Merz Aesthetics team onsite at launch
Photo credit: Merz Aesthetics
We Recommend for You:
